We're here to fix what's broken in weight care
Embla is a fully managed benefit that delivers lasting weight loss with less GLP-1 through behavior-first care, expert coaching, and data-led design.
.webp)
What we do
Embla partners with self-funded employers and health plans to deliver behavior-first, clinically validated GLP-1 care. Our fully managed benefit combines low-dose GLP-1s, 1:1 behavioral coaching, and structured tapering, giving members better outcomes at a fraction of the typical pharmacy cost.
Our model
Most weight loss programs treat medication as the solution. We treat it as a tool.
Embla's treat-to-target model pairs GLP-1s with intensive behavioral coaching, so members need less medication to achieve more meaningful, lasting results.
The proof is in the TRIM study: 2,694 real-world participants, 64 weeks, peer-reviewed and published in Diabetes, Obesity and Metabolism. Average weight loss of 16.7% at less than half the typical semaglutide dose. And 78.5% successfully tapering off medication entirely.
Leaders in
GLP-1 research
We’re committed to advancing obesity care through our leadership in GLP-1 research. By sharing real-world insights from our programs, we help define how GLP-1s can be used more effectively — and more affordably — in workforce health strategies.
Our impact
Four years in, we've supported over 30,000 lives, published peer-reviewed research in one of the largest real-world GLP-1 studies to date, and succesfully expanded into the US employer market.
30,000+ lives improved
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Published in Diabetes, Obesity and Metabolism
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
2 health system partnerhips
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
5 benefits consultant partnerships
Our mission is to transform how obesity is treated — at work and beyond
We challenge the one-size-fits-all approach to weight loss by combining behavioral science, clinical care, and compassionate coaching. The result? Smarter, more sustainable care that improves employee health and lowers long-term costs.
Our story
Embla was founded in 2021 by Laust, a health tech entrepreneur with a successful IPO behind him, and Nicholas, a cardiologist and former innovation lead at Novo Nordisk.
Together, they saw what was missing in obesity care — not more medication, but better support around it. They built Embla to prove that behavioral science, clinical rigor, and smart use of GLP-1s could deliver results that medication alone never would.
Since then, Embla has supported over 30,000 individuals across Europe, conducted six clinical studies, establishing the biggest GLP-1 dataset in the world, and succesfully expanded into the US employer market — where self-funded employers and health plans are looking for exactly what we've built.
